Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, incorporated in Ireland, filed this Current Report on Form 8-K on August 10, 2017. The filing announces the release of earnings results for the second quarter ended July 1, 2017. The detailed financial results are contained in the press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures used by the company.
The Company utilizes non-GAAP measures to evaluate ongoing operating trends and facilitate comparability. These measures exclude items such as:
- Impairment charges
- Amortization expense related to acquired intangible assets
- Restructuring and acquisition/integration charges
- Loss on early debt extinguishment and related hedge losses
- Operating results from exited or held-for-sale businesses (including Entocort and Israel API business)
- Unusual litigation and contingent consideration adjustments
Material Changes and Adjustments
The filing outlines specific adjustments made to reported results for the three months ended July 1, 2017, compared to the prior period (ended July 2, 2016). Notable items excluded in the current period include loss on early debt extinguishment, gain on divestitures, and Entocort operating results. The prior period adjustments included losses from equity method investments and operating results attributable to held-for-sale businesses.
Guidance, Outlook, and Risks
The Company has provided 2017 full-year guidance, which incorporates adjustments for amortization, debt extinguishment, restructuring, impairment, and specific business unit results (Israel API, Entocort). Management uses these adjusted measures for planning, forecasting, and determining compensation. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical values on revenue, net income, and earnings per share.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of excluded items like debt extinguishment and restructuring.
- Assess the impact of the Entocort and Israel API business results on the reported figures.
- Confirm the details of the 2017 full-year guidance provided in the attached press release.
- Check for any updates on the loss on early debt extinguishment and its effect on liquidity.